8-K Announcements
6Material company update
Feb 26, 2026·SEC
Material company update
Jan 22, 2026·SEC
Material company update
Nov 6, 2025·SEC
Janux Therapeutics, Inc.(JANX)Earnings, Financials & Key Ratios
JANX•NASDAQ
$14.62
$883M mkt cap·Price updated May 6, 2026
AboutJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.Show more
- Revenue$10M-5.6%
- EBITDA-$158M-62.9%
- Net Income-$158M-128.5%
- EPS (Diluted)-1.83-43.0%
- EBITDA Margin-1576.67%-72.5%
- Operating Margin-1576.67%-68.9%
- Net Margin-1576.67%-142.0%
- ROE-15.93%-57.8%
- ROIC-15.34%+0.2%
- Debt/Equity0.02+2.8%
JANX Key Insights
Janux Therapeutics, Inc. (JANX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 15.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
JANX Price & Volume
Janux Therapeutics, Inc. (JANX) stock price & volume — 10-year historical chart
Loading chart...
JANX Growth Metrics
Janux Therapeutics, Inc. (JANX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years5.11%
TTM68.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-128.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-42.97%
Return on Capital
10 Years-32.12%
5 Years-17.23%
3 Years-16.68%
Last Year-15.61%
JANX Recent Earnings
Janux Therapeutics, Inc. (JANX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (88%)
Q1 2026Latest
Feb 26, 2026EPS
$0.51
Est $0.65
+21.5%
Revenue
$8M
Est $83,333
+9356.0%
Q4 2025
Nov 6, 2025EPS
$0.39
Est $0.60
+35.0%
Revenue
$10M
Q3 2025
Aug 7, 2025EPS
$0.55
Est $0.48
-14.6%
Revenue
—
Est $300,000
Q2 2025
May 8, 2025EPS
$0.38
Est $0.43
+11.6%
Revenue
—
Est $660,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.51vs $0.65+21.5% | $8Mvs $83,333+9356.0% |
| Q4 2025 | Nov 6, 2025 | $0.39vs $0.60+35.0% | $10M |
| Q3 2025 | Aug 7, 2025 | $0.55vs $0.48-14.6% | —vs $300,000 |
| Q2 2025 | May 8, 2025 | $0.38vs $0.43+11.6% | —vs $660,000 |
Based on last 12 quarters of dataView full earnings history →
JANX Peer Comparison
Janux Therapeutics, Inc. (JANX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TNGX | 3.21B | 23.62 | -27.15 | 48.29% | -162.85% | -50.3% | 0.10 | |
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% |
Compare JANX vs Peers
Janux Therapeutics, Inc. (JANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JANX Income Statement
Janux Therapeutics, Inc. (JANX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Revenue Growth % | - | - | - | 136.79% | -6.14% | 30.99% | -5.55% |
| Cost of Goods Sold | 6K | 13K | 0 | 841K | 1.96M | 2.06M | 0 |
| COGS % of Revenue | - | - | - | 9.77% | 24.19% | 19.46% | - |
| Gross Profit | -6K▲ 0% | -13K▼ 116.7% | 3.64M▲ 28076.9% | 7.77M▲ 113.7% | 6.13M▼ 21.1% | 8.53M▲ 39.2% | 0▼ 100.0% |
| Gross Margin % | - | - | 100% | 90.23% | 75.81% | 80.54% | - |
| Gross Profit Growth % | - | -116.67% | 28076.92% | 113.67% | -21.14% | 39.16% | -100% |
| Operating Expenses | 3.77M | 4.83M | 36.57M | 74.86M | 79.11M | 107.38M | 167.67M |
| OpEx % of Revenue | - | - | 1005.39% | 869.28% | 978.68% | 1014.12% | 1676.67% |
| Selling, General & Admin | 772K | 1.79M | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| SG&A % of Revenue | - | - | 284% | 258.5% | 323.39% | 387.67% | 417.71% |
| Research & Development | 3M | 3.04M | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| R&D % of Revenue | - | - | 721.39% | 620.54% | 679.48% | 645.9% | 1258.96% |
| Other Operating Expenses | 0 | 0 | 0 | -841K | -1.96M | -2.06M | 0 |
| Operating Income | -3.77M▲ 0% | -4.84M▼ 28.4% | -32.93M▼ 579.9% | -67.09M▼ 103.7% | -72.98M▼ 8.8% | -98.85M▼ 35.4% | -157.67M▼ 59.5% |
| Operating Margin % | - | - | -905.39% | -779.04% | -902.87% | -933.58% | -1576.67% |
| Operating Income Growth % | - | -28.43% | -579.93% | -103.74% | -8.78% | -35.45% | -59.51% |
| EBITDA | -3.77M | -4.83M | -32.82M | -66.25M | -71.02M | -96.79M | -157.67M |
| EBITDA Margin % | - | - | -902.28% | -769.28% | -878.68% | -914.12% | -1576.67% |
| EBITDA Growth % | - | -28.29% | -579.42% | -101.88% | -7.21% | -36.27% | -62.9% |
| D&A (Non-Cash Add-back) | 6K | 13K | 113K | 841K | 1.96M | 2.06M | 0 |
| EBIT | -3.77M | -6.58M | -32.93M | -67.09M | -72.98M | -98.85M | 0 |
| Net Interest Income | 0 | 0 | 257K | 4.03M | 14.69M | 29.85M | 0 |
| Interest Income | 233K | 206K | 257K | 4.03M | 14.69M | 29.85M | 0 |
| Interest Expense | 233K | 206K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -233K | -1.94M | 257K | 4.03M | 14.69M | 29.85M | 0 |
| Pretax Income | -4M▲ 0% | -6.78M▼ 69.4% | -32.67M▼ 381.6% | -63.06M▼ 93.0% | -58.29M▲ 7.6% | -68.99M▼ 18.4% | -113.63M▼ 64.7% |
| Pretax Margin % | - | - | -898.32% | -732.22% | -721.18% | -651.62% | -1136.25% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.24M▲ 0% | -6.78M▼ 60.1% | -32.67M▼ 381.6% | -63.06M▼ 93.0% | -58.29M▲ 7.6% | -68.99M▼ 18.4% | -157.67M▼ 128.5% |
| Net Margin % | - | - | -898.32% | -732.22% | -721.18% | -651.62% | -1576.67% |
| Net Income Growth % | - | -60.11% | -381.6% | -93.01% | 7.56% | -18.36% | -128.52% |
| Net Income (Continuing) | -4M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -157.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10▲ 0% | -0.16▼ 60.0% | -0.79▼ 393.8% | -1.52▼ 92.4% | -1.32▲ 13.2% | -1.28▲ 3.0% | -1.83▼ 43.0% |
| EPS Growth % | - | -60% | -393.75% | -92.41% | 13.16% | 3.03% | -42.97% |
| EPS (Basic) | -0.10 | -0.16 | -0.79 | -1.52 | -1.32 | -1.28 | -1.83 |
| Diluted Shares Outstanding | 41.61M | 41.61M | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Basic Shares Outstanding | 41.61M | 41.61M | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
JANX Balance Sheet
Janux Therapeutics, Inc. (JANX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 658K | 16.06M | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M |
| Cash & Short-Term Investments | 658K | 7.81M | 374.96M | 327.02M | 344.03M | 1.03B | 966.57M |
| Cash Only | 658K | 7.81M | 35.58M | 51.43M | 19.2M | 430.61M | 52.33M |
| Short-Term Investments | 0 | 0 | 339.38M | 275.59M | 324.82M | 594.57M | 914.23M |
| Accounts Receivable | 0 | 8M | 0 | 700K | 0 | 5.38M | 0 |
| Days Sales Outstanding | - | - | - | 29.67 | - | 185.5 | - |
| Inventory | 0 | 0 | 0 | -700K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 5.42M | 5.21M | 0 | 9.32M |
| Total Non-Current Assets | 21K | 155K | 2.81M | 31.57M | 31.17M | 27.85M | 25.68M |
| Property, Plant & Equipment | 21K | 155K | 1.6M | 29.36M | 27.84M | 24.15M | 22.25M |
| Fixed Asset Turnover | - | - | 2.28x | 0.29x | 0.29x | 0.44x | 0.45x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 816K | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 1.21M | 1.39M | 3.33M | 3.7M | 3.42M |
| Total Assets | 679K▲ 0% | 16.22M▲ 2288.4% | 379.82M▲ 2242.1% | 364.01M▼ 4.2% | 380.41M▲ 4.5% | 1.06B▲ 179.0% | 1B▼ 5.6% |
| Asset Turnover | - | - | 0.01x | 0.02x | 0.02x | 0.01x | 0.01x |
| Asset Growth % | - | 2288.37% | 2242.13% | -4.16% | 4.5% | 179.05% | -5.65% |
| Total Current Liabilities | 4.63M | 3.18M | 12.8M | 16.51M | 13.03M | 17.46M | 25M |
| Accounts Payable | 267K | 428K | 2.46M | 2.16M | 2.42M | 4.03M | 4.97M |
| Days Payables Outstanding | 16.24K | 12.02K | - | 937.02 | 452.56 | 713.34 | - |
| Short-Term Debt | 4M | 0 | 0 | 0 | 0 | 0 | 2.39M |
| Deferred Revenue (Current) | 0 | 1.95M | 5.16M | 5.41M | 1.71M | 0 | 0 |
| Other Current Liabilities | 82K | 338K | 2.37M | 5.51M | 3.3M | 11.68M | 22.6M |
| Current Ratio | 0.14x | 5.05x | 29.46x | 20.14x | 26.80x | 59.21x | 39.04x |
| Quick Ratio | 0.14x | 5.05x | 29.46x | 20.18x | 26.80x | 59.21x | 39.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4M | 27.67M | 700K | 26.76M | 23.02M | 21.28M | 19.75M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 19.75M |
| Capital Lease Obligations | 0 | 0 | 0 | 24.54M | 23.02M | 21.28M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4M | 21.62M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 8.62M | 30.86M | 13.5M | 43.27M | 36.06M | 38.73M | 44.74M |
| Total Debt | 4M | 0 | 194K | 25.3M | 24.54M | 23.02M | 22.14M |
| Net Debt | 3.34M | -7.81M | -35.39M | -26.12M | 5.34M | -407.58M | -30.2M |
| Debt / Equity | - | - | 0.00x | 0.08x | 0.07x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -16.18x | -23.51x | - | - | - | - | - |
| Total Equity | -7.94M▲ 0% | -14.64M▼ 84.3% | 366.33M▲ 2602.6% | 320.74M▼ 12.4% | 344.35M▲ 7.4% | 1.02B▲ 197.0% | 956.82M▼ 6.4% |
| Equity Growth % | - | -84.26% | 2602.58% | -12.44% | 7.36% | 197.02% | -6.45% |
| Book Value per Share | -0.19 | -0.35 | 8.88 | 7.73 | 7.82 | 19.03 | 15.44 |
| Total Shareholders' Equity | -7.94M | -14.64M | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M |
| Common Stock | 1K | 1K | 41K | 42K | 46K | 59K | 60K |
| Retained Earnings | -7.96M | -14.74M | -47.41M | -110.47M | -168.76M | -237.76M | -351.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -270K | -1.53M | 665K | 2.16M | 4.32M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JANX Cash Flow Statement
Janux Therapeutics, Inc. (JANX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.83M | -4.37M | -16.98M | -42.92M | -50.58M | -43.81M | 0 |
| Operating CF Margin % | - | - | -466.76% | -498.4% | -625.7% | -413.81% | - |
| Operating CF Growth % | - | -14.13% | -288.56% | -152.84% | -17.83% | 13.37% | 100% |
| Net Income | -4M | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | 0 |
| Depreciation & Amortization | 6K | 13K | 113K | 841K | 1.96M | 2.06M | 0 |
| Stock-Based Compensation | 6K | 72K | 6.91M | 17.2M | 20M | 33.02M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 233K | 1.94M | -169K | -2.18M | -7.69M | -10.59M | 0 |
| Working Capital Changes | -69K | 389K | 8.84M | 4.28M | -6.55M | 685K | 0 |
| Change in Receivables | 0 | -8M | 8M | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 831K | 0 | 0 | 0 | 0 |
| Change in Payables | 4K | 14K | 2.14M | -294K | 277K | 1.58M | 0 |
| Cash from Investing | 0 | 0 | -340.96M | 58.27M | -41.19M | -258.02M | -300.98M |
| Capital Expenditures | 0 | 0 | -1.48M | -6.45M | -1.85M | -359K | 0 |
| CapEx % of Revenue | - | - | 40.75% | 74.84% | 22.89% | 3.39% | - |
| Acquisitions | 0 | 0 | 339.48M | -64.71M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -339.48M | 64.71M | 0 | 0 | -300.98M |
| Cash from Financing | 4M | 11.52M | 386.52M | 500K | 59.55M | 713.24M | 4.95M |
| Debt Issued (Net) | 4M | 2.5M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 500K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 70K | 1.81M | 0 | 3.02M | 14.97M | 4.95M |
| Net Change in Cash | 172K▲ 0% | 7.16M▲ 4059.9% | 28.59M▲ 299.5% | 15.84M▼ 44.6% | -32.22M▼ 303.4% | 411.4M▲ 1376.8% | -378.27M▼ 191.9% |
| Free Cash Flow | -3.83M▲ 0% | -4.37M▼ 14.1% | -18.46M▼ 322.5% | -49.37M▼ 167.5% | -52.42M▼ 6.2% | -44.17M▲ 15.7% | 0▲ 100.0% |
| FCF Margin % | - | - | -507.51% | -573.24% | -648.58% | -417.2% | - |
| FCF Growth % | - | -14.13% | -322.48% | -167.46% | -6.19% | 15.74% | 100% |
| FCF per Share | -0.09 | -0.10 | -0.45 | -1.19 | -1.19 | -0.82 | - |
| FCF Conversion (FCF/Net Income) | 0.90x | 0.64x | 0.52x | 0.68x | 0.87x | 0.64x | - |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
JANX Key Ratios
Janux Therapeutics, Inc. (JANX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -18.58% | -18.36% | -17.53% | -10.09% | -15.93% |
| Return on Invested Capital (ROIC) | - | - | -16.01% | -16.09% | -16.99% | -15.37% | -15.34% |
| Gross Margin | - | - | 100% | 90.23% | 75.81% | 80.54% | - |
| Net Margin | - | - | -898.32% | -732.22% | -721.18% | -651.62% | -1576.67% |
| Debt / Equity | - | - | 0.00x | 0.08x | 0.07x | 0.02x | 0.02x |
| Interest Coverage | -16.18x | -23.51x | - | - | - | - | - |
| FCF Conversion | 0.90x | 0.64x | 0.52x | 0.68x | 0.87x | 0.64x | - |
| Revenue Growth | - | - | - | 136.79% | -6.14% | 30.99% | -5.55% |
JANX SEC Filings & Documents
Janux Therapeutics, Inc. (JANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
JANX Frequently Asked Questions
Janux Therapeutics, Inc. (JANX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Janux Therapeutics, Inc. (JANX) reported $17.9M in revenue for fiscal year 2025.
Janux Therapeutics, Inc. (JANX) saw revenue decline by 5.6% over the past year.
Janux Therapeutics, Inc. (JANX) reported a net loss of $157.7M for fiscal year 2025.
Dividend & Returns
Janux Therapeutics, Inc. (JANX) has a return on equity (ROE) of -15.9%. Negative ROE indicates the company is unprofitable.
Explore More JANX
Janux Therapeutics, Inc. (JANX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates